ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BVXP Bioventix Plc

4,900.00
0.00 (0.00%)
Last Updated: 07:45:34
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4,900.00 4,800.00 5,000.00 4,900.00 4,900.00 4,900.00 0.00 07:45:34
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 12.82M 8.37M 1.6071 30.49 255.26M
Bioventix Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 4,900p. Over the last year, Bioventix shares have traded in a share price range of 3,450.00p to 5,060.00p.

Bioventix currently has 5,209,333 shares in issue. The market capitalisation of Bioventix is £255.26 million. Bioventix has a price to earnings ratio (PE ratio) of 30.49.

Bioventix Share Discussion Threads

Showing 1401 to 1424 of 1575 messages
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older
DateSubjectAuthorDiscuss
28/3/2022
09:03
Oops - well they are scientists!
Suet

suetballs
28/3/2022
08:21
Interims ...

"Board is pleased to announce a first interim dividend of 52p per share which represents a 20% increase on the interim dividend paid last year (43 pence per share). The shares will be marked ex-dividend on the 7 April 2021 and the dividend will be paid on 22 April 2021 to shareholders on the register at close of business on 8 April 2021."

!!

piedro
15/3/2022
08:52
Good news for our investment. Perhaps a catalyst for the share price Looking forward to results.

hxxps://www.bioworld.com/articles/516919-cardinor-secures-ce-mark-for-cardiovascular-risk-test?v=preview

doctor888
20/1/2022
12:10
John, you were predicting a tenner 2 years ago. You might be right eventually, but not yet :-)
stepone68
24/11/2021
15:35
Yep - almost every company carries a covid health warning - not unexpected surely.
Suet

suetballs
24/11/2021
14:35
The core business is linked to routine testing at hospitals around the world and this has undoubtedly been affected by the COVID-19 pandemic. The timing of a return to normality is uncertain


From last rns

Not pleasing

onjohn
24/11/2021
14:06
LOL - get back to Staffline - hot your 140p target yet?
igbertsponk
24/11/2021
14:01
Lack of diagnosis due to covid will reduce prescribing and hence profit warning

Profit warn will not be taken well

onjohn
24/11/2021
13:49
Can't see it crashing 50% in a day either. Demand for healthcare is only going to increase and the approvals regimes mean long windows of opportunity.
stepone68
24/11/2021
13:46
Yeah there is no quick win here. It went from undervalued to overvalued and will now settle down hopefully somewhere around thirty quid. Reinvest the dividends if you want some growth, and hope that at least one of the current research projects pays off.
stepone68
24/11/2021
10:06
Thanks for the replies chaps - sit and wait then.
On Avon I was lucky to get out at £30 and no way will I be getting back in.
Suet

suetballs
24/11/2021
09:22
Never a short term trade. One to buy and put away like a young claret.
igbertsponk
24/11/2021
09:20
Short term no because this company does not communicate a lot - if previous years are a guide the next trading statement will be Interim results at the end of March. Between now and then it will just be the mood of the market that moves the share price
sharw
24/11/2021
09:06
Can anyone see any short term upside here?
Got in late and currently sitting on a 20% loss.
Suet

suetballs
21/11/2021
17:58
Worth following him on all companies he writes up. Remarkably thorough and careful with his opinions
apad

apad
21/11/2021
17:23
Fair play - that is a really good write up on a company.
trident5
21/11/2021
16:15
BIOVENTIX: FY 2021 Results Unveil Record H2 Profit (+14%) While Finite Troponin Income Shifts Longer-Term Perspective Towards Pyrene Project And Alzheimer’s Research #BVXP


"Valuing the pipeline at a negative £5m seems about right if annual R&D costs are £1.2m and research commercialisation is not expected until 2025 at the earliest"

tmfmayn
18/11/2021
17:56
Good spot. The FY 2020 Employees total costs in note 6 seems to have been accidentally copied and pasted into note 7!

Coincidentally I have just watched a newly posted video with Terry Smith, where he asks the question, "does anyone read the accounts anymore?"(from point 12:30 in the video):

robinnicolson
16/11/2021
19:43
Note 7 (Directors Rem) just doesn't add up. By about £600k. Error, nothing suspicious. Obviously they don't read here or they'd have corrected by now. I've sent them a message.
igbertsponk
16/11/2021
18:12
Less interested market means less buyers and sellers and less liquidity. Could also be the usual market maker shenanigans.
doctor888
16/11/2021
17:26
Igbert - I've not looked at the note, but is the comparative issue related to the additional 700k revenue from a couple of years ago which was backdated?

Jim - don't know, sorry.

stepone68
16/11/2021
15:57
Why is the spread increasing?
jimboyce
11/11/2021
16:15
Though Note 7 of the accounts needs a bit of work! Comparative total is somewhat out. OOPS!
igbertsponk
11/11/2021
16:11
They don't waste oodles on such presentation nonsense. They bill customers, spend a very little on costs and distribute the vast majority of sales revenue as dividends. And have done for eons now. Best run company on the exchange.
igbertsponk
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com